On May 12, 2026, a change in terminology marked a major shift in women’s health. In a paper published in The Lancet, Polycystic Ovarian Syndrome (PCOS) was renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), reflecting more than a decade of global research and the experiences of over 14,000 patients and clinicians. The updated terminology reframes one of the most common endocrine conditions affecting over 1 million Canadian women.
For years, the name PCOS has been a notoriously inconsistent and misleading term, reducing a complex, hormonal condition to a narrow focus on the ovaries. This left many patients navigating a diagnosis that never quite fit, receiving care for reproductive symptoms while metabolic care went unaddressed. The terminology also left many women excluded or undiagnosed altogether, despite meeting the criteria for the condition. In fact, a 2019 Cochrane review suggested that up to 70% of women with PMOS may never receive a formal diagnosis, meaning the true prevalence may be significantly higher than currently recognized.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” explains Professor Helena Teede, who led the name change process.
The new name, PMOS, provides healthcare providers with a clear direction for proactive, personalized care.
PCOS is now PMOS
PMOS is a complex, multisystem condition that involves interacting endocrine, metabolic, and reproductive pathways. Far more than just an ovarian disorder, its key features include:
- Polyendocrine Abnormalities: The condition is defined by hyperandrogenism, meaning high levels of androgens (like testosterone) from both the ovaries and adrenal glands. This hormonal imbalance can cause symptoms like hirsutism, acne, and alopecia. Central neuroendocrine changes can also disrupt the menstrual cycle.
- Metabolic Disruption: Insulin resistance is a core feature, affecting up to 85% of people with PMOS, including 75% of lean women. This drives further androgen production and increases the risk for type 2 diabetes, high blood pressure, and cardiovascular disease.
- Ovarian Dysfunction: While not just an ovarian issue, hormonal and metabolic disruptions impair follicular maturation, leading to the accumulation of small antral follicles, irregular ovulation, and infertility.
The Name Changed. The Care Model Should Too.
The transition to polyendocrine metabolic ovarian syndrome was chosen deliberately through a process that prioritized scientific accuracy, patient dignity, and clinical utility. It is a direct response to historical gaps in care. Canadian research, for example, has documented delays in diagnosis and care plans that addressed fertility concerns while leaving metabolic risks largely unexamined or in some cases, left the individual with no diagnosis or treatment at all.
The PMOS reclassification also reflects a broader shift in women’s healthcare: moving beyond a predominantly reproductive framework toward a more integrated understanding of hormonal and metabolic health. This shift may also help remove the stigma associated with this condition being about an anatomical abnormality and encourage a more comprehensive understanding of the multiple body systems involved in the disease process.
The women who will benefit most from the PMOS reclassification are those who receive care from providers who understand that hormonal complexity, metabolic risk, reproductive goals, and psychological wellbeing are interconnected — that this is “not simply a reproductive disease with reproductive consequences,” but one that affects many other important body systems, particularly cardiovascular health, and should be considered through a heart health lens to optimize preventive care.
The hope is that with this new research and guidance, this type of care will become the rule rather than the exception.
What a new standard of care looks like
The Global Name Change Consortium has outlined a three-year implementation strategy, with full integration into international clinical guidelines by 2028. That transition period allows healthcare providers to build the proactive care models that PMOS demands.
- Earlier and more accurate diagnosis: Grounded in the full clinical picture rather than the presence or absence of ovarian cysts.
- Comprehensive screening: Metabolic and cardiovascular screening as a standard component of PMOS care, prioritizing prevention.
- Integrated care teams: Bringing together endocrinology, nutrition, mental health, and reproductive medicine within a client’s personalized care plan.
- Long-term monitoring: Recognizing that PMOS is a chronic condition requiring ongoing management and longitudinal care across a woman’s lifespan.
- Empowered patients: Ensuring patients understand what their diagnosis means and what proactive management looks like across decades.
New Hope for Women’s Healthcare
For the women who have waited years to be heard, who have educated themselves online, and who are still searching for a diagnosis, this news brings hope. Renaming PCOS to PMOS acknowledges the full complexity of the condition these women live with. It also points toward the benefit that comprehensive and collaborative care can achieve.
This way of caring for the whole person has always been at the heart of our work at Harrison, and the new name does not change that. The shift to PMOS gives women’s healthcare providers a shared framework to keep pace with advancing research and a growing range of care options. For clients at Harrison living with PMOS, it supports a more complete understanding of care: earlier diagnosis, more personalized treatment, and steady support throughout their lives. Our hope is that this kind of care continues to evolve and becomes the norm for women everywhere, supported by practitioners across the field.
